The tweet was deleted by the author.
But we saved everything 🙂.
Zymeworks has announced that Health Canada has approved its HER2-targeted therapy for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer.
This advancement marks a significant milestone for the company's development team and partners, underscoring years of dedicated research and effort in the field of oncology treatment. The approval reflects a growing trend towards innovative therapies in the fight against cancer.